Comparative Pharmacology
Head-to-head clinical analysis: CARISOPRODOL versus GABLOFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARISOPRODOL versus GABLOFEN.
CARISOPRODOL vs GABLOFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
GABLOFEN (baclofen) is a GABA-B receptor agonist that reduces spinal reflex transmission and inhibits excitatory neurotransmitter release.
250-350 mg orally 3 times daily and at bedtime
10 mg orally three times daily, may increase by 10 mg/day every 3 days to a maximum of 80 mg/day (20 mg four times daily).
None Documented
None Documented
Clinical Note
moderateCarisoprodol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluticasone propionate."
Clinical Note
moderateCarisoprodol + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Carisoprodol."
Clinical Note
moderateCarisoprodol + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Carisoprodol."
Clinical Note
moderateCarisoprodol + Ketoconazole
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Terminal half-life 5-7 hours; clinically relevant for dosing interval of every 6-8 hours.
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
Renal: 70-80% unchanged; biliary/fecal: <5% as metabolites. Total clearance 2.5-3.0 L/h.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The metabolism of Ketoconazole can be decreased when combined with Carisoprodol."